EVA Pharma’s roots stretch back over a hundred years.

thumbnail_Pharmacy.jpeg

Pharmacy.jpeg

Our History

Our experienced leadership team keeps us on track.

thumbnail_Find_Out_More_Leaders.png

Find_Out_More_Leaders.png

Meet our Leaders

EVA Pharma’s success is based on its dynamic team, Our people are our power.

thumbnail_1704997569480.jfif

1704997569480.jfif

Life at EVA Pharma

Are you a Journalist or Media Representative and need information about us? Please feel free to get in touch with our PR Team

thumbnail_pexels-kaboompics-com-6335@2x.png

pexels-kaboompics-com-6335@2x.png

Media Contact 

Event

thumbnail_EVA-Q12026_websitebanner-CDMOLIVE 1.png

EVA-Q12026_websitebanner-CDMOLIVE 1.png

Contract manufacturing PharmaVenue althcare company operating across 70+

CDMO Live

thumbnail_hero-section-ss.jpg

hero-section-ss.jpg

CPHI Worldwide 2025 Frankfurt EVA Pharma is a global healthcare company operating across 70+ countries, dedicated

CPHI Worldwide 2025

thumbnail_EVAxMIS_Ann-01-web-eng (1).png

EVAxMIS_Ann-01-web-eng (1).png

KSA Saudi Made localization Saudization Empowering health research and development

Saudi Made 2025

<div>
Under this partnership, EVA Pharma to import, market, promote and distribute BeiGene’s flagship Oncology medicines BRUKINSA and TEVIMBRA in Egypt.&nbsp; &nbsp;
DUBAI, CAIRO, Egypt - 27th March 2025 – <a href="https://evapharma.com/" target="_blank" rel="noopener">EVA Pharma</a>,&nbsp; one of the fastest-growing healthcare organizations in the Middle East and Africa, and BeiGene International GmbH (an affiliate of <a href="https://beigene.com/" target="_blank" rel="noopener">BeiGene</a> Ltd., NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd, have announced a strategic partnership to expand treatment options for cancer patients in Egypt. &nbsp; &nbsp;
Under the terms of the agreement, EVA Pharma will begin by launching BRUKINSA (zanubrutinib), a second-generation Bruton Tyrosine Kinase (BTK) inhibitor. Another medicine to be introduced under this partnership is TEVIMBRA (tislelizumab), an immunotherapy that targets the PD-1 pathway. According to the U.S. Food and Drug Administration (FDA), BRUKINSA is approved for the treatment of certain blood cancers, while TEVIMBRA is approved for the treatment of solid tumors.,1,2&nbsp;
&nbsp;
“At BeiGene, our mission is to expand access to innovative oncology treatments for patients worldwide. This partnership with EVA Pharma is a significant step toward achieving that goal in Egypt.&nbsp;
&nbsp;
By combining BeiGene’s advanced therapies, such as BRUKINSA and TEVIMBRA, with EVA Pharma’s strong regional expertise, we are forming a powerful alliance to meet the urgent needs of cancer patients. Together, we are not only delivering hope but also working to raise the standard of cancer care in Egypt and across the region,” said Mohammed Al Kapany, General Manager of BeiGene’s Middle East and Africa (MENA) region.&nbsp;
&nbsp;
“We are eager to provide cancer patients with innovative and accessible therapies. That’s why we are partnering with BeiGene — to improve patient outcomes by increasing access to critical treatments. It is also worth noting that this marks the third global pharmaceutical company to choose EVA Pharma as a partner of choice, a reflection of the trust and credibility we have built over the years,” said Dr. Amgad Talaat, Strategic Alliances Director and Saudi Arabia Cluster Head, EVA Pharma.&nbsp;
&nbsp;
<a href="https://gco.iarc.who.int/media/globocan/factsheets/populations/818-egypt-fact-sheet.pdf" target="_blank" rel="noopener">The Global Cancer Observatory (GLOBOCAN 2022) reports over 366,000 cancer cases in Egypt, with nearly 95,300 cancer-related deaths.</a>3 This partnership was established to address the significant unmet need for advanced oncology treatments in Egypt, reflecting the shared commitment of EVA Pharma and BeiGene to expand access to innovative cancer care.&nbsp;
&nbsp;
It also represents a major milestone in improving access to these innovative therapies across the region.&nbsp;
&nbsp;
Under the agreement, EVA Pharma will lead the importation, marketing, and medical promotion of BeiGene’s oncology therapies in Egypt — treatments that have shown meaningful progress in advancing cancer care. By leveraging EVA Pharma’s deep expertise in distribution, medical affairs,&nbsp;&nbsp;
and regional market dynamics, this collaboration aims to make these innovative options more accessible to patients in Egypt.&nbsp;
&nbsp;
EVA Pharma and BeiGene are also committed to supporting healthcare professionals through ongoing medical education and resources to help optimize patient outcomes. This partnership represents a significant step toward strengthening cancer care in Egypt and contributing to broader efforts to reduce the global cancer burden — delivering renewed hope to patients and their families.&nbsp;
&nbsp;
About TEVIMBRA®(tislelizumab)&nbsp;
&nbsp;
TEVIMBRA is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcγ) receptors on macrophages, helping the body’s immune cells detect and fight tumors.&nbsp;
TEVIMBRA is the foundational asset of BeiGene’s solid tumor portfolio and has shown potential across multiple tumor types and disease settings. The global TEVIMBRA clinical development program includes almost 14,000 patients enrolled to date in 34 counties and regions across 66 trials, including 20 registration-enabling studies. TEVIMBRA is approved in more than 42 countries, and more than 1.3 million patients have been treated globally.&nbsp;
&nbsp;
About BRUKINSA®(zanubrutinib)&nbsp;
&nbsp;
BRUKINSA is an orally available, small molecule inhibitor of Bruton’s tyrosine kinase (BTK) designed to deliver complete and sustained inhibition of the BTK protein by optimizing bioavailability, half-life, and selectivity. With differentiated pharmacokinetics compared with other approved BTK inhibitors, BRUKINSA has been demonstrated to inhibit the proliferation of malignant B cells within a number of disease-relevant tissues. &nbsp;
 &nbsp;
BRUKINSA has the broadest label globally of any BTK inhibitor and is the only BTK inhibitor to provide the flexibility of once or twice daily dosing. The global BRUKINSA clinical development program includes about 6,000 patients enrolled in 30 countries and regions across more than 35 trials. BRUKINSA is approved in more than 70 markets, and more than 100,000 patients have been treated globally. &nbsp;
&nbsp;
About EVA Pharma&nbsp;
&nbsp;
EVA Pharma is dedicated to improving access to affordable, high-quality medicines around the world, focusing on three core pillars: innovation, development and sustainable access. The company leverages cutting-edge technology at two research centers bringing first-of-its-kind&nbsp;&nbsp;
&nbsp;
capabilities to the Middle East and Africa including mRNA research and development from AI prediction to biologic products.&nbsp;
&nbsp;
With a 5,000-strong team of professionals, EVA Pharma produces more than one million healthcare products a day at four state-of-the-art manufacturing facilities, which are internationally recognized for innovation, and have been approved by multiple regulatory agencies.&nbsp;
&nbsp;
Guided by a relentless drive to ensure sustainable access to pressing, yet unmet, disease areas, the company’s product portfolio focuses on twelve therapeutic areas: Anti-infectives, metabolic health, bone, neuroscience, oncology, respiratory, gynecology, urology and andrology, pediatrics, ophthalmology, gastrointestinal tract, family medicine to meet both local and international demand.&nbsp;
&nbsp;
EVA Pharma is one of the fastest-growing healthcare companies in the Middle East and Africa, with an extensive pan-African presence, while operating in more than 70 countries worldwide.&nbsp;
&nbsp;
For more information, please visit: <a href="http://www.evapharma.com/" target="_blank" rel="noopener">www.evapharma.com</a> &amp; <a href="https://www.evapharma.com/newsroom" target="_blank" rel="noopener">https://www.evapharma.com/newsroom</a> or follow us on <a href="https://www.facebook.com/Evapharma/" target="_blank" rel="noopener">Facebook</a>, <a href="https://www.linkedin.com/company/eva-pharma/" target="_blank" rel="noopener">LinkedIn</a> &amp; <a href="https://www.instagram.com/eva.pharma/" target="_blank" rel="noopener">Instagram</a>  &nbsp;
&nbsp;
About BeiGene&nbsp;
&nbsp;
BeiGene, which plans to change its name to BeOne Medicines Ltd., is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of nearly 11,000 colleagues spans five continents. To learn more about BeiGene, please visit <a href="https://www.beigene.com/" target="_blank" rel="noopener">www.beigene.com</a> and follow us on <a href="https://www.linkedin.com/search/results/all/?fetchDeterministicClustersOnly=true&amp;heroEntityKey=urn%3Ali%3Aorganization%3A106535894&amp;keywords=beone%20medicines&amp;origin=RICH_QUERY_TYPEAHEAD_HISTORY&amp;position=0&amp;searchId=6405c2b3-1782-41dd-8a8b-fb8b6dde8a40&amp;sid=-Nh&amp;spellCorrectionEnabled=true" target="_blank" rel="noopener">LinkedIn</a>.&nbsp;
&nbsp;
Forward-Looking Statements&nbsp; &nbsp;
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeiGene’s ability to deliver transformative therapies to patients with cancer; the potential of&nbsp;&nbsp;
BRUKINSA® (zanubrutinib) and TEVIMBRA® (tislelizumab) to address critical needs in oncology; the future development, regulatory approvals, and commercial success of BRUKINSA and TEVIMBRA; and BeiGene’s plans, commitments, aspirations, and goals under the heading “About BeiGene.”&nbsp;
Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene’s ability to demonstrate the efficacy and safety of its medicines; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approvals; BeiGene’s ability to achieve commercial success for its approved medicines and investigational drug candidates; its ability to obtain and maintain protection of intellectual property; its reliance on third parties to conduct development, manufacturing, commercialization, and other services; its limited experience in&nbsp;&nbsp;
&nbsp;
&nbsp;
obtaining regulatory approvals and commercializing pharmaceutical products; and its ability to obtain additional funding and achieve and maintain profitability.&nbsp;
&nbsp;
Additional information is available in BeiGene’s most recent quarterly report on Form 10-Q, as well as subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date hereof, and BeiGene undertakes no duty to update such information unless required by law.&nbsp;
&nbsp;
Issued by:&nbsp;
EVA Pharma, El Sharekat St., El Opera-Abdeen – Cairo - Egypt&nbsp; &nbsp; BeiGene International GmbH, Dubai Science Park, Al Barsha - Al Barsha South - Dubai - United Arab Emirates.&nbsp;
Date of Preparation:&nbsp;
26 March 2025&nbsp;
***************************************************************************************&nbsp;
References&nbsp;
<ol style="margin-top: 0in;" start="1" type="1">
<li class="MsoNormal">BRUKINSA® (zanubrutinib) - U.S. Food and Drug Administration. FDA Approves Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. January 19, 2023. Available at: <a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zanubrutinib-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma" target="_blank" rel="noopener">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zanubrutinib-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma</a>&nbsp;</li>
</ol>
<ol style="margin-top: 0in;" start="2" type="1">
<li class="MsoNormal">TEVIMBRA® (tislelizumab) - U.S. Food and Drug Administration. Drug Trials Snapshots: TEVIMBRA. March 14, 2024. Available at: <a href="https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-tevimbra" target="_blank" rel="noopener">https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-tevimbra</a>&nbsp;</li>
</ol>
<ol style="margin-top: 0in;" start="3" type="1">
<li class="MsoNormal">International Agency for Research on Cancer. GLOBOCAN 2020: Egypt Fact Sheet. World Health Organization; 2021. Available at: <a href="https://gco.iarc.who.int/media/globocan/factsheets/populations/818-egypt-fact-sheet.pdf" target="_blank" rel="noopener">https://gco.iarc.who.int/media/globocan/factsheets/populations/818-egypt-fact-sheet.pdf</a>.&nbsp; Accessed 21 March 2025.&nbsp;</li>
</ol>
&nbsp;
END&nbsp;
&nbsp;
For media inquiries contact - BeiGene:&nbsp;&nbsp;
&nbsp;
Louise Carter Rosa Soto&nbsp;
Email: <a href="mailto:louise.carter@beigene.com" target="_blank" rel="noopener">louise.carter@beigene.com</a> Email: <a href="mailto:louise.carter@beigene.com" target="_blank" rel="noopener">rosa.soto@beigene.com</a>&nbsp;
&nbsp;
For media inquiries contact – EVA Pharma:&nbsp;&nbsp;
&nbsp;
Ahmed Ellewa&nbsp;
Email: <a href="mailto:ahmed.ellewa@evapharma.com" target="_blank" rel="noopener">ahmed.ellewa@evapharma.com</a>&nbsp;
&nbsp;
&nbsp;
&nbsp;
</div>

thumbnail_IMG_9167.JPG

IMG_9167.JPG

Press Release

EVA Pharma and BeiGene Announce a Strategic Partnership to Bring Innovative Oncology Therapies to Patients in Egypt

&nbsp;
CAIRO – May 22, 2023 -- EVA Pharma participated in the 76th World Health Assembly (WHA) side event on the role of local manufacturing in improving access to noncommunicable disease (NCD) medicines. The event, held on May 22nd in Geneva, served as an influential platform to address the paramount issues surrounding medication accessibility. Among the pivotal points emphasized during the panel discussion was the urgent need for streamlining registration processes and implementing harmonized medicines registration systems to minimize delays and ensure swift access to life-saving medications for those in need.
&nbsp;
The panel discussion addressed the escalating burden of diabetes mellitus (DM) in Africa, where 24 million adults are currently living with DM according to the International Diabetes Federation (IDF). With projections estimating that 55 million people in Africa will have diabetes by 2045, the region is facing the largest increase in diabetes rates globally, as highlighted by the World Health Organization (WHO).
Access to affordable insulin remains a key barrier to successful treatment, resulting in unnecessary complications and premature deaths. In response to this critical issue, EVA Pharma started a collaboration with Eli Lilly and Company in December 2022 to expand sustainable access to high-quality, affordable human and analogue insulin and reach annually at least one million people living with type 1 and type 2 diabetes in 56 low- and middle-income countries (LMICs), most of which are in Africa.&nbsp;
&nbsp;
“We strive to save and improve millions of lives by offering accessible, high-value medicines and healthcare solutions that address local patients’ needs”, emphasized Dr. Riad Armanious, CEO of EVA Pharma. “By joining forces of all health advocates and taking synergistic actions we can implement real change. When we enhance regional manufacturing capabilities, we ensure that high-quality medicine reaches the patients who need it the most.”
&nbsp;
&nbsp;
The panel also featured esteemed panelists such as Dr. Bente Mikkelsen, Director of the NCD Programme at the World Health Organization (WHO), Ms. Loren Becker, Senior Director of Global Health Policy at Eli Lilly and Company, Dr. Rogerio Gaspar, Director of the Regulation and Prequalification Department at WHO, and Dr. Jean Kaseya, Director General of the Africa CDC.
&nbsp;
Keynote speakers at the event included H.E. Dr. Khaled Abdel Ghaffar, the Minister of Health and Population of Egypt, and Loyce Pace, Assistant Secretary of Health and Human Services for Global Affairs of the United States.
&nbsp;
EVA Pharma's participation in this WHA side event demonstrates its commitment to improving access to NCD medicines and its proactive role in fostering partnerships to address healthcare challenges in Africa. The company's dedication to meeting the needs of local communities aligns with the global effort to enhance healthcare systems and ensure that life-saving treatments reach all who require them.
&nbsp;
About EVA Pharma
EVA Pharma empowers the fight for health and well-being in communities around the world. With a 5,000-strong team of professionals, the company produces more than one million healthcare products a day at its state-of-the-art manufacturing facilities, which are equipped with cutting-edge technology, are internationally recognized for innovation, and have been approved by multiple regulatory agencies.
The company’s product portfolio focuses on pressing, yet unmet, disease areas, such as diabetes and cardiovascular diseases, oncology, neuroscience, ophthalmology, anti-infectives, bone and pain, hepatology, and reproductive health, to meet both local and international demand.
EVA Pharma is one of the fastest-growing healthcare companies in the Middle East and Africa, with an extensive pan-African presence, while operating in more than 40 countries worldwide.
For more information, please visit: www.evapharma.com &amp; https://www.evapharma.com/newsroom or follow us on LinkedIn&nbsp;&nbsp;
&nbsp;
Media Contact:&nbsp;
Ahmed Ellewa | Public Relations Head | ahmed.ellewa@evapharma.com | +20-1000-053-643
&nbsp;

thumbnail_MicrosoftTeams-image (161).png

MicrosoftTeams-image (161).png

EVA Pharma Highlights Commitment to Improving Access to NCD Medicines at the 76th WHA Side Event on Role of Local Manufacturing

Cairo, Egypt – February 5, 2025 –Africa’s EVA Pharma, France’s DNA Script, and Belgium’s Quantoom Biosciences have signed a Memorandum of Understanding today, on the sidelines of the 2nd Vaccine and Other Health Products Manufacturing Forum for African Union Member States, organized by Africa CDC and hosted by the Egyptian United Procurement Authority (UPA) in Cairo. This collaboration aims to develop the first ever digital-to-biologics, end-to-end mRNA production platform, focusing on nucleic acid-based vaccines and therapeutics, including mRNA and saRNA vaccines for both human and animal health.&nbsp;
The platform, taking place in Egypt, will integrate DNA Script’s enzymatic DNA synthesis technologies with Quantoom’s Ntensify® mRNA synthesis and Ncapsulate® formulation technologies, combined with EVA Pharma’s vaccine development, top notch GMP sterile manufacturing expertise and commercialization capabilities. The collaboration addresses critical market needs, including rapid responses to infectious diseases outbreaks and routine immunizations.. The shared vision is to produce 100 million doses of RNA-based vaccines annually, fostering localization and strengthening regional autonomy in biopharmaceutical manufacturing. This collaboration will focus on developing a next generation, saRNA-based vaccines, targeting both human and animal health under the One Health approach to create a stronger defense against zoonotic diseases from the source.&nbsp;
This initiative will contribute to achieve Africa CDC’s target of 60% local vaccine production by 2040 and Egypt’s ambitious goal to manufacture 385 million vaccine doses annually by 2030, establishing itself as a global leader in vaccine production. It also supports public health resilience and food security across Africa and the Middle East.&nbsp;&nbsp;
“This moment will reshape African and global health security as we know it.” Said Dr. Riad Armanious, CEO of EVA Pharma, expressing his enthusiasm. “Our cross-continental collaboration will empower patients with next-generation, scalable, and versatile solutions that transform what once took years into a process achievable in weeks. This is not tomorrow’s promise, it is today’s reality: with an operational biologics manufacturing site producing 100 million vials and 1.5 billion doses of animal health vaccine already commercialized, we have the infrastructure to streamline vaccine production using groundbreaking mRNA technology and ensuring unparalleled safety.”
According to Marc Montserrat, CEO of DNA Script,&nbsp;&nbsp;“Our collaboration with EVA Pharma and Univercells-Quantoom to implement our proprietary enzymatic DNA synthesis technology directly supports the mission to accelerate vaccine development and delivery worldwide, and more broadly aligns with our vision to make biology programmable. By dramatically reducing the time needed to produce DNA templates, and by enabling the synthesis of longer and more complex DNA sequences, we're helping ensure that innovative vaccine technology can reach those at highest risk during emerging epidemics more rapidly than ever before.”&nbsp;
José Castillo, CEO of Quantoom Biosciences, added: “This collaboration showcases the transformative power of combining complementary expertise across borders. Together, we are not only advancing RNA technologies but also addressing global health inequities by making life-saving vaccines and therapeutics accessible to underserved populations.”&nbsp;
Hala Audi, CEO of Unizima, echoed this sentiment: “EVA Pharma is already showing the world the power of investing in the biopharma sector to create health and wealth in Africa and the Middle East. We are proud to support the tech transfer of some of the best technology for DNA and RNA manufacturing to Egypt, as the next chapter in their growth.”&nbsp;
This MoU reflects a strong commitment to advance global health equity and foster sustainable biopharma development. By combining their strengths, the partners aim to deliver versatile, scalable, and impactful solutions. These will shape the future of healthcare in Egypt and beyond, while contributing to economic resilience and regional pandemic preparedness and response.&nbsp;
&nbsp;
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;=ENDS=&nbsp;
About EVA Pharma&nbsp;
EVA Pharma is dedicated to improving access to affordable, high-quality medicines around the world, focusing on three core pillars: innovation, development and sustainable access. The company leverages cutting-edge technology at two research centers bringing first-of-its-kind capabilities to the Middle East and Africa including mRNA research and development from AI prediction to biologic products.&nbsp;
With a 5,000-strong team of professionals, EVA Pharma produces more than one million healthcare products a day at four state-of-the-art manufacturing facilities, which are internationally recognized for innovation, and have been approved by multiple regulatory agencies.&nbsp;
Guided by a relentless drive to ensure sustainable access to pressing yet unmet disease areas, the company’s product portfolio focuses on twelve therapeutic areas: Anti-infectives, metabolic health, bone, neuroscience, oncology, respiratory, gynecology, urology and andrology, pediatrics, ophthalmology, gastrointestinal tract, family medicine to meet both local and international demand.&nbsp;
EVA Pharma is one of the fastest-growing healthcare companies in the Middle East and Africa, with an extensive pan-African presence, while operating in more than 70 countries worldwide.&nbsp;
For more information, please visit: www.evapharma.com &amp; https://www.evapharma.com/newsroom or follow us on Facebook, LinkedIn &amp; Instagram
&nbsp;
About EVA Pharma’s mRNA Innovation Hub&nbsp;
EVA Pharma has notably focused on localizing innovation in recent years through investing in research infrastructure and financing. The company has established an in-house research and development footprint, including its mRNA Innovation Hub, which is fully equipped to handle the complete mRNA vaccine development lifecycle—from digital sequencing to final drug formulation. This includes antigen selection, protein engineering, mRNA construct design, process development, innovative formulation delivery systems, and analytical method development.&nbsp;
&nbsp;
About DNA Script&nbsp;
DNA Script is at the forefront of transforming biological research through advanced enzymatic DNA synthesis technology. We provide pioneering solutions for DNA production, including our cutting-edge SYNTAX® DNA printer and our enzymatic synthesis technology that enables the production of longer and more complex DNA sequences. Our innovations are driving progress across critical scientific domains, including mRNA vaccine development, cell and gene therapy, and broader biomolecular research. By offering researchers unprecedented capabilities to synthesize high-quality DNA sequences, we are accelerating discoveries that have the potential to revolutionize healthcare, biotechnology, and scientific understanding.&nbsp;
&nbsp;
About Quantoom Biosciences&nbsp;
Quantoom Biosciences is leading the revolution in mRNA- and saRNA-based vaccines and therapeutics by providing turnkey solutions for (sa)mRNA &amp; LNP manufacturing. Its cutting-edge Ntensify® technology enables the production and purification of mRNA through a fully integrated, scalable system that combines processes, equipment, reagent mixes, and disposables. This solution supports the entire spectrum of mRNA production, from R&amp;D to commercial manufacturing. Launched in 2023, Ntensify has already been widely adopted across multiple continents, showcasing its global appeal. Quantoom Biosciences is also developing the Ncapsulate® technology for mRNA-LNP formulation and purification, aiming to significantly increase the accessibility and affordability of mRNA-based drugs. Located in Belgium, Quantoom Biosciences thrives in a dynamic biotech ecosystem, driving innovation in mRNA production to make life-changing therapies available to everyone, everywhere. More info : www.quantoom.com&nbsp;
&nbsp;
About Unizima&nbsp;
Unizima is a trusted consultancy specialized in public and private partnerships for establishing bioproduction facilities and develop the workforce in emerging biotech ecosystems. As a partner to biopharma manufacturers, governments, and global health agencies, Unizima enables the sustainable production of biologics—including vaccines, monoclonal antibodies, and recombinant protein. From project inception to technology transfer and training, Unizima integrates all necessary elements to bring biomanufacturing initiatives to life. More info: www.unizima.com&nbsp;&nbsp; 
Contact details&nbsp;
EVA Pharma&nbsp;
Marina Mansour&nbsp;
Corporate communications professional&nbsp;
Marina.mansour@evapharma.com 
DNA Script
Rachel Macmaster, PhD
Director, Global Marketing
<span style="font-size: 12.0pt; line-height: 115%; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Aptos; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;">&nbsp;publicrelations@dnascript.com&nbsp;&nbsp;
&nbsp;
Quantoom Biosciences / Unizima&nbsp;
Jonathan Lecocq&nbsp;
MarCom Manager&nbsp;
j.lecocq@quantoom.com&nbsp;
+32 476 81 12 44&nbsp;
&nbsp;
Disclosure Statement&nbsp;&nbsp;
The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified using forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law. &nbsp;

thumbnail_WhatsApp Image 2025-02-05 at 10.06.15 2.jpeg

WhatsApp Image 2025-02-05 at 10.06.15 2.jpeg

Africa and Europe Join Forces to Revolutionize RNA-based Vaccines and Therapeutics Production: MoU Signed Between EVA Pharma, DNA Script, Quantoom Biosciences

Are you a Healthcare professional?

Press Release

EVA Pharma and BeiGene Announce a Strategic Partnership to Bring Innovative Oncology Therapies to Patients in Egypt

2025-03-26

Top News

Press Release

2025-03-26

Press Release

2023-05-21

Press Release

2025-02-04

Top News

Press Release

EVA Pharma and BeiGene Announce a Strategic Partnership to Bring Innovative Oncology Therapies to Patients in Egypt

2025-03-26